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Learning objectives
After reading this article you should be able to:
•	 Define	and	differentiate	between	the	terms	
myalgia, myositis, myopathy and rhabdomyolysis
•	 List	the	common	drugs	involved	in	causing	 
muscle disorders
•	 Describe	the	mechanistic	action	by	which	
the most common myotoxic drugs cause their 
respective dysfunction
•	 Recognise	risk	factors	for	the	different	drug	
induced muscle disorders
•	 Modify	the	risk	for	drug	induced	muscle	disorders	
and manage symptoms if present
Competencies addressed: 3.1.2, 3.2.2, 4.2.2, 4.2.3
John Smithson is a Lecturer, Discipline of Pharmacy, School of 
Pharmacy and Molecular Sciences, James Cook University.
Drug induced musculoskeletal disorders can potentially 
affect the spectrum of anatomical structures including bone, 
connective tissue and the musculature. Skeletal muscles 
represent a significant proportion of the body’s mass, receive 
a large fraction of blood supply, and are metabolically 
highly active. This tissue therefore has significant exposure 
to circulating drugs, which has the potential to cause 
drug induced disorders ranging from trivial myalgias and 
asymptomatic elevations in creatine kinase through to life 
threatening rhabdomyolysis with myoglobin induced renal 
failure.1 Accepted definitions of muscle related side effects 
may differ slightly from study to study, though the following 
definitions are a commonly accepted consensus2, 3 and are 
used throughout this article.
Myalgia (muscle pain) is characterised by diffuse muscle 
pain, tenderness and cramps with the presence or absence 
of muscle weakness. Myalgia is not accompanied by 
elevations in creatine kinase. While the presentation may 
be mild, symptoms such as muscle cramps and aches or 
non-specific muscle pain may be a precursor to more serious 
musculoskeletal conditions such as rhabdomyolysis.4 
Myositis is the inflammation of voluntary muscle fibres and has 
muscle symptoms similar to myalgia but is accompanied by an 
elevation in serum creatine kinase (CK). The two main sources 
of creatine kinase are myocardium (relatively small contributor) 
and skeletal muscle which accounts for around 94% of creatine 
kinase.5 The presence of this marker for muscle damage may 
result from exercise, physical muscle trauma, inherited or 
acquired diseases or extrinsic drug causes.
Myopathy is a general term referring to any disease of 
muscles and is sometimes used interchangeably with 
myositis. Myopathies can be acquired or inherited and can 
occur at birth or in later life. There is a strong correlation 
between many drugs and myopathy. Features of drug induced 
myopathy are polymorphous and include:3,6
•	 Fatigue
•	 Generalised	muscle	pain
•	 Muscle	tenderness
•	 Muscle	weakness
•	 Significantly	elevated	serum	creatine	kinase	 
(CK) > 10 x upper limit of normal (ULN)
•	 Nocturnal	cramping
•	 Tendon	pain.
The symptoms of myopathy tend to be worse at night and 
are aggravated by exercise. Myopathy should be considered 
when serum CK levels are more than 10 x ULN, or in patients 
with increases in serum CK (less than 10 x ULN) accompanied 
by symptoms of myalgia. Muscle biopsy is non-specific but 
may reveal muscle fibre inflammation, atrophy and in some 
cases necrosis and regeneration. Muscle biopsy may be 
useful where CK remains elevated post drug withdrawal.
‘Needle myopathy’ is a focal myopathy due to traumatic 
necrosis, haematoma formation or low grade infections 
resulting from intramuscular injections. Chronic focal 
myopathy can occur after repeated injections at the same 
site caused by needle trauma, pH of the injected solution or 
the inherent myotoxicity of the drug injected.4
Rhabdomyolysis usually appears as an acute event; 
however it may have an insidious onset over a period 
of weeks. Pain (not a prominent feature in up to 50% of 
cases), muscle weakness, muscle swelling, myoglobinuria 
(presenting as tea or cola coloured urine, elevated serum 
and urine myoglobin levels) and a marked elevation in serum 
CK (between 10 and 100 x ULN) are the hallmarks of the 
syndrome. Secondary renal failure may follow myoglobinuria 
and results from the release of intracellular contents 
(enzymes and myoglobin) from damaged myocytes into the 
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Table 2. – Broad classification of drug induced myalgia and example drugs
Classification and example mechanism Example drugs and toxins
Necrotising myopathies – reduced essential co-enzyme production, myocyte 
membrane changes and increased oxidation
HMG CoA-reductase inhibitors 
(statins), fibrates, nicotinic acid
Corticosteroid myopathy – disruption of RNA synthesis Fluorinated steroids such as 
dexamethasone and triamcinolone
Mitochondrial myopathies – inhibition of mitochondrial DNA polymerase Zidovudine
Lysosomal storage myopathy – increased lysosomal activity degrading muscle fibres Hydroxychloroquine, amiodarone
Antimicrotubular myopathy – accumulation of lysosomes and autophagic vacuoles Colchicine, vincristine
Hypokalaemic myopathy – disruption of water and electrolyte homeostasis Diuretics, oral contraceptives
Inflammatory myopathies – activation of immune system, resembles autoimmune disease D-penicillamine and interferon-α
Adapted from Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle & Nerve. 2003;27(2):142-56.
Table 1. Common drugs that may cause myalgia or myopathy4, 7
Class Family Examples
Antibiotics Quinolones ciprofloxacin, norfloxacin, ofloxacin
Miscellaneous cotrimoxazole, isoniazid, minocycline, pipercillin-tazobactam
Anti-neoplastic agents 
and related compounds
Anti-metabolites cladribine, cytarabine, methotrexate
Miscellaneous docetaxel, paclitaxel, letrozole, leuprorelin, procarbazine, 
vincristine, 
Anti-ulcer agents Histamine H2 receptors 
antagonists and proton pump 
inhibitors
cimetidine, ranitidine, nizatidine
pantoprazole
Antiviral agents Antiretroviral agents indinavir, lamivudine, ritonavir, saquinavir, stavudine, zidovudine
Other gancyclovir
Corticosteroids fluorinated steroids such as dexamethasone, betamethasone and 
triamcinolone, but may be any steroid taken by injection, inhalation 
or oral ingestion
Cytokines
Bisphosphonates alendronate, ibandronate, pamidronate, risedronate
Lipid-lowering drugs Fibrates fenofibrate, gemfibrozil, nicotinic acid
Statins atorvastatin, fluvastatin, pravastatin, simvastatin
Antifungal agents amphotericin B, terbinafine
Antithyroid drugs carbimazole, propylthiouracil, 
Immunosuppressants cyclosporine, uromonab-CD3, mycophenolate mofetil, tacrolimus
Cardiovascular agents amiodarone, beta-blockers, bumetanide, captopril, diuretics, 
enalapril, eprosartan, lercanidipine, methyldopa
Miscellaneous baclofen, chloroquine, colchicine, ethanol, iloprost, isotretinoin, 
ivermectin, infliximab, mebeverin, mefloquine, metoclopramide, 
montelukast, nafarelin, naltrexone, penicillamine, phenytoin, 
salmeterol, sildenafil, somatropin, suxamethonium, tacrine, 
tianeptine, triazolam.
Table adapted from Lee A, ed. Adverse Drug Reactions. 2nd ed. Great Britain: Pharmaceutical Press; 2009;296, & Bannwarth B. Drug-induced myopathies. Expert Opinion on Drug Safety. 2002;1(1):69.
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circulation which are toxic to the kidney (and other organs). 
Other sequelae of rhabdomyolysis include hyperkalaemia, 
hypocalcaemia, disseminated intravascular coagulation, 
cardiomyopathy, respiratory failure and severe metabolic 
acidosis.4 The management of rhabdomyolysis requires 
discontinuation of the causative agent, and supportive 
therapy including intravenous fluids, correction of electrolyte 
abnormalities and alkalinisation of the urine.4 Patients 
generally recover completely if the syndrome is recognised 
early and treated appropriately.6
Recognising drug induced muscle disease
A high degree of clinical suspicion in patients presenting 
with muscle pain offers pharmacists the opportunity 
to identify extrinsic drug causes. Early recognition and 
appropriate management often prevents a severe outcome 
with complete resolution commonly following. The 
relationship between the muscle disorder and a drug is 
suggested by several clinical features:4, 7
•	 Lack	of	pre-existing	muscular	symptoms
•	 Presence	of	a	reasonable	temporal	relationship	between	
the start of treatment or change of dose and the 
appearance of symptoms
•	 Lack	of	any	other	cause	for	the	myopathy
•	 Partial	or	compete	resolution	of	symptoms	after	the	 
drug is withdrawn. 
Additionally, there are a number of patient factors that 
increase the risk of drug induced myotoxicity. They include:
•	 Advanced	age	(>	70	years)
•	 The	administration	of	a	single	or	multiple	myotoxic	drugs
•	 High	doses	of	myotoxic	drugs
•	 Female	gender
•	 Thyroid	disease
•	 Existing	hepatic	or	renal	disease
•	 Surgery	(perioperative	period)
•	 Existence	of	metabolic	muscle	disease
•	 Genetic	polymorphisms.
Studies into genetic risk factors associated with lipid-
lowering drug-induced myopathies by Vladutiu et al. (2006), 
found four prominent biochemical abnormalities on muscle 
biopsy findings of patients with statin induced myalgia. 
CPT (carnitine palmitoyltransferase) II deficiency and 
CoQ10 (coenzyme Q10) deficiency were the most frequent 
abnormalities observed. Respiratory (cellular) chain defects 
and carnitine abnormalities are the remaining common 
biochemical abnormalities. Patients with these metabolic 
muscle conditions were found to be over-represented in 
patient populations with statin induced myopathy. A higher 
percentage of individuals with multiple abnormalities had 
serum CK levels >10 x ULN.8
CoQ10 deficiency is the most common muscle defect. 
It is an essential cofactor in mitochondrial (cellular) 
respiration in the electron transport chain.
CPT II deficiency is a mitochondrial abnormality most 
likely acquired due to exposure to statins rather than 
genetic inheritance. CPT II is located in the mitochondrial 
membrane where it facilitates the transport of long-chain 
fatty acids into the mitochondrion.8
Myotoxic drugs. Numerous drugs cause myotoxic effects 
by various mechanisms making it unrealistic to discuss them 
all. Table 1 lists drugs that are known to be myotoxic in some 
individuals. The primary cause is direct toxicity and this is 
often (but not always) dose-related. Secondary causes include 
electrolyte disturbances, increased or excessive energy 
requirements or insufficient nutrient supply. Muscle damage 
may be generalised when drugs are taken orally, or local for 
those drugs injected via intramuscular route.9 Some drugs cause 
these effects more frequently than others. Corticosteroid and 
cholesterol lowering agent myopathies are probably the most 
common cause of drug related muscle pain. Other drugs worthy of 
mention include zidovudine, colchicine, amiodarone, cyclosporin, 
D-penicillamine and valproic acid. Table 1.2 briefly outlines the 
most common classifications of drug induced myalgia.
Common myotoxic drugs and their presentation
Corticosteroid induced myalgia. Chronic use of oral 
corticosteroids can cause proximal muscle weakness and 
atrophy of the lower limbs and is probably the most common 
cause of toxic muscle disease. The course is often slow and 
mild and is often associated with other chronic systemic side 
effects of corticosteroids.10 Inhaled steroids or doses ≥ 10 mg 
of prednisolone (or equivalent) daily for more than 30 days 
have been observed to be myotoxic.9 A second, more severe 
form of corticosteroid induced myopathy presents as acute 
severe weakness that usually affects critically ill patients in 
ICU. The fluorinated corticosteroids such as dexamethasone, 
betamethasone and triamcinolone have a higher propensity to 
induce myopathy compared with non-fluorinated corticosteroids.4,10
Table 3. Factors that increase risk for 
corticosteroid induced myalgia
Risk factors for steroid induced myalgia
•	Fluorinated	steroids	such	as	dexamethasone,	
betamethasone and triamcinolone
•	Accumulative	dose
•	Concomitant	use	of	other	myotoxic	drugs
•	Electrolyte	disturbances	(manifesting	as	muscle	weakness)
•	Sepsis	or	multi-organ	failure.
The commonly accepted cause of corticosteroid myotoxicity 
is disruption of RNA synthesis, leading to type-2 muscle fibre 
atrophy and muscle necrosis. Another possible mechanism 
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identified is the induction of breakdown of muscle proteins 
by calpain (a calcium-activated protease) and anti-
ubiquitin antibodies.10 Table 3 outlines the risk factors for 
corticosteroid induced myalgia.
Cholesterol Lowering Agents Myopathy (CLAM). Lipid-
lowering agents such as fibrates, nicotinic acid derivatives 
and statins are associated with myopathy, and while they 
are generally well tolerated and safe,11 the large volume of 
prescriptions for these agents make myalgia or myopathy 
an observable event. The reported incidence in patients 
using all lipid-lowering therapy varies. The occurrence rate 
of myalgia among statin users varies between randomised 
controlled trials which suggest a rate of 1.5 to three percent 
and prospective clinical studies which suggest rates between 
10-13%.3, 12 By 2007, the Therapeutic Goods Administration 
had received 5,846 adverse reaction reports implicating 
a statin, of which one-third described a muscle disorder 
previously defined.13 In two large trials involving simvastatin, 
the Scandinavian Simvastatin Survival Study (4S) trial and 
the Heart Protection Study of cholesterol lowering with 
Simvastatin (HPS) trial rates of myotoxicity in the simvastatin 
group were similar to that of the placebo group (< 0.1%)  
(it should be noted this trial excluded patients with high risk 
factors). In the ExPRESS (The examination of probands and 
relatives in statin studies with familial hypercholesterolemia) 
trial the observed rate of drug related myalgia was 8.9% and 
no cases of myopathy were reported.14
A small retrospective study by Hansen, et al.15 found the 
mean duration of therapy before onset of symptoms was 
6.3 months and the mean duration of myalgia after stopping 
statin therapy was 2.3 months. The conclusion drawn was 
that muscle symptoms that develop in a patient who has 
been taking statins for several years are unlikely to have 
been caused by these drugs and symptoms will largely 
resolve on withdrawal of the drug.6,15
The use of combined lipid-lowering drugs increases the risk of 
myopathy and results in a more severe clinical presentation, 
very occasionally leading to rhabdomyolysis.16 Studies reported 
by Saleh and Seidman (2003) report CLAM takes place in 
0.5% patients taking one lipid lowering therapy and up to 5% 
of patients taking combination lipid lowering therapy. The 
Adverse Drug Reaction Advisory Committee (ADRAC) received 
91 reports of rhabdomyolysis with simvastatin and 26 with 
atorvastatin by 2004. An Australian analysis of PBS data by 
Ronaldson, et al. found the incidence of rhabdomyolysis at 
2.1 cases per 1,000,000 prescriptions for simvastatin and 
1.3 per 1,000,000 prescriptions for atorvastatin.17 These 
numbers indicate rhabdomyolysis occurs very rarely. The risk of 
rhabdomyolysis is increased with advanced age, statin dose ≥ 
40mg daily, concurrent cyclosporine, gemfibrozil and diltiazem 
administration and diabetes.18 Fibrates inhibit phase 2 
glucuronidation reaction in statin metabolism as well as being 
inherently myotoxic themselves.19 At times when recalcitrant 
or very high cholesterol levels dictate the use of combination 
statin/fibrate therapy, fenofibrate may be a more suitable 
alternative to gemfibrozil due to its lower tendency toward 
pharmacokinetic interactions with statins.11,20
The mechanism of CLAM is not well understood but is attributed 
to the reduced synthesis of mevalonate which is a precursor to a 
number of important components of the cell membrane, as well 
as being a precursor molecule for steroid hormones, vitamin D 
and bile acids. Endogenous cholesterol biosynthesis occurs in 
the endoplasmic reticulum and cytosol and is shown in Figure 1. 
The mechanism by which statins induce muscle disorders is a 
result of one or a combination of the following;2,3,10
•	 An	increase	in	the	fluidity	of	the	myocyte	membrane	due	
to changes in cholesterol.
•	 Impaired	synthesis	of	compounds	in	the	cholesterol	
pathway, particularly of heme A and CoQ10 synthesis 
resulting in mitochondrial dysfunction, reduced energy 
and eventual cell death.
•	 Increased	activity	of	caritine	palmityl	transferase	leading	
to caritine and fatty acid deficiency and damage to 
muscle fibres.
Risk factors for statin induced myopathy
The two main independent risk factors for statin induced 
myopathy are dose (or increased bioavailability) and 
lipophilicity of the statin. The greater the lipophilicity of a 
statin, the greater penetration into muscle tissue, which 
Figure 1. The biosynthetic pathway of 
cholesterol and other co-metabolites
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explains in part their myotoxic effects. This suggests the 
use of a hydrophilic agent in patients with pre-existing 
muscle disease may be prudent.3 However myopathy has 
been reported with largely hydrophilic statins such as 
pravastatin, demonstrating that lipophilicity is not the sole 
factor in predicting myotoxic potential. This is explained by 
the observation that while poor lipophilicity limits passive 
diffusion into myocytes, it also dictates a low hepatic 
extraction ratio, and in the case of pravastatin, results 
in a mean expected plasma concentration up to 10 times 
higher than the more lipophilic statins.2,21 Table 4 lists the 
lipophilicity of commonly used statins.
Table 4. Lipophilicity of statins
Lipophilic agents Hydrophilic agents
simvastatin (most lipophilic agent) pravastatin
atorvastatin rosuvastatin
fluvastatin
Any factor that increases the serum concentration or 
bioavailability (for example drug interactions decreasing 
metabolism or clearance or changes in drug transport 
proteins) has the potential to increase the risk of myopathy.3 
Table 5 outlines some patient and statin characteristics that 
increase the risk of statin induced myopathy and Table 6 
outlines some drugs that increase the bioavailability of 
commonly used statins.
Table 5. Factors that increase the risk of  
statin-induced myopathy2–4,12,14
Patient characteristics Statin properties
Increasing age (>70–80 years)
Female gender
Renal insufficiency
Hypothyroidism
Excessive consumption of 
grapefruit or cranberry juice
Concomitant medications
Diabetes or other multisystem 
disease
Hepatobiliary dysfunction
Low body mass index
Vigorous exercise
Excessive alcohol consumption
Major surgery or trauma.
Increasing lipophilicity
High bioavailability
Limited protein binding
High statin dose
Increasing lipophilicity
High bioavailability
Limited protein binding
Table 6. Examples of common drugs that inhibit the 
CYP450 pathway or independently cause myositis3,12
Drugs that inhibit CYP3A4
(metabolic pathway 
for simvastatin and 
atorvastatin)
Drugs that inhibit CYP2C9
(metabolic pathway 
for fluvastatin and 
rosuvastatin)
macrolide antibiotics
azole antifungals
HIV protease inhibitors
fluoxetine
verapamil
warfarin 
grapefruit juice
fibrates
warfarin
amiodarone
cimetidine
trimethoprim/
sulfamethoxazole fluoxetine
fluvoxamine
isoniazid
metronidazole
zafirlukast
itraconazole
ketoconazole
Current NHFA/CSANZ* guidelines recommend baseline 
creatine kinase levels be taken before starting lipid lowering 
therapy, and if symptoms such as muscle weakness or pain 
are reported, compared against a second level. Routing 
serial monitoring is not recommended, although it may be 
appropriate in those on multiple medicines known to cause 
myalgia or inhibit CYP450 3A4, patients with advanced age 
or with kidney dysfunction.11
Management of statin induced myopathy
If a patient displays symptoms of myopathy, conditions unrelated 
to statin therapy should be ruled out, and CK level should be 
assessed. A CK level > 10 x ULN is a predictor of rhabdomyolysis 
and these patients should be investigated for elevated urine 
myoglobin levels, deteriorating renal function and thyroid 
function. Their statin therapy should be ceased immediately, 
and the benefits of continued lipid lowering therapy should be 
weighed against the risks of further myotoxicity. These patients 
may sometimes be recommenced on a lower dose, or prescribed 
lower-risk alternative therapy after symptom resolution. For 
patients whose CK is elevated < 10 x ULN, the dose may be 
continued at the same or lower dose providing muscle symptoms 
are tolerable. If intolerable, the drug should be ceased, and 
the patient observed until symptoms resolve and CK returns to 
normal. They may then be recommenced on the same drug, at a 
lower dose, which is often uneventful.19
Conditions unrelated to statin therapy3
•	Bursitis
•	Myofascial	pain
•	Muscle	strain
•	Osteoarthritis
•	Radiculopathy
•	Tendinitis.
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 Small scale research has demonstrated positive results 
for the use of CoQ10 supplementation as a treatment for 
statin induced myopathy; however there remains insufficient 
Key points for pharmacists managing statin induced myopathy3
•	Slightly	increased	creatine	kinase	is	common	in	the	general	
population.
•	Myopathy	that	develops	after	a	patient	has	taken	statins	
for several years is unlikely to be caused by these drugs
•	Thyroid	stimulating	hormone	should	be	checked	in	patients	
on statins who develop a myopathy because hypothyroidism 
is a common cause of hypercholesterolaemia and raised 
creatine kinase
•	If	muscle-related	symptoms	or	raised	creatine	kinase	
concentrations persist after statin therapy is stopped, 
further specialist investigation and intervention is required
•	Drugs	that	inhibit	CYP3A4	increase	the	risk	of	statin	
induced myopathy
•	Combination	statin	and	fibrate	therapy	increases	myopathy	
risk
•	Monitoring	for	serum	CK	is	not	routinely	indicated	but	
patients should have CK levels taken at commencement of 
statin therapy.
evidence for routine use of CoQ10 supplementation in patients 
taking statins. It is thought certain subgroups of patients 
susceptible to statin induced myopathy may benefit, and these 
patients may be candidates for CoQ10 supplementation.2
Other drug causes of myopathy
A mitochondrial myopathy caused by zidovudine occurs in 
patients with human immunodeficiency virus (HIV). Zidovudine 
myopathy resembles HIV-associated myopathy, with patients 
presenting with myalgia, fatigue and limb-girdle weakness 
which is sometimes associated with either normal or 
moderately elevated CK levels.7 It has a reported incidence 
of between 2 and 17 % of patients dependant on duration 
of therapy.10 The myopathy results from a mitochondrial 
dysfunction as a result of inhibition of mitochondrial DNA 
polymerase (zidovudine acts as a false substrate for viral 
reverse transcriptase but also for mitochondrial DNA 
polymerase). The myopathy is both reversible and dose 
related.9 It is treated by ceasing zidovudine and corticosteroid 
therapy if myositis is present.10
Chloroquine and hydroxychloroquine myopathies are most 
likely induced by increased lysosomal activity within the myocyte 
and present as a painless, insidious weakness beginning in 
the proximal leg muscles and later the arms and face. It was 
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1. Which of the following statements about myopathy is 
INCORRECT?
a. Symptoms of myopathy include muscle tenderness and weakness, 
fatigue. They may be worse at night and aggravated by exercise.
b. Myopathy is not associated with significant elevations of  
creatine kinase.
c. Risk for drug induced muscle myopathy is increased in the elderly, 
females and those with thyroid disease.
d. Fibrates, corticosteroids and statins are implicated in myopathy.
e. None of the above.
2. Which of the following statements about statin induced 
myopathy and rhabdomyolysis is/are TRUE?
a. Statins have a greater chance of inducing myopathy when therapy 
has been taken for many years.
b. While the risk of CLAM is relatively small, pharmacists should have 
a high degree of clinical suspicion in patients taking statins and 
presenting with muscle complaints.
c. The risk of myopathy is increased for the lipophilic statins such as 
simvastatin and atorvastatin.
d. Statin induced myopathy is not linked to dose, and occurs 
irrespective of statin dose.
e. (b) and (c) only.
Questions  (A score of 4 out of 5 attracts one credit point.)
3. Corticosteroid induced myopathy has been associated with 
which of the following?
a. High accumulative dose of corticosteroid.
b. Fluorinated steroids such as dexamethasone.
c. Both inhaled and oral doses of corticosteroids.
d. Long duration of corticosteroid therapy.
e. All of the above.
4. Which of the following factors is generally NOT indicative 
of a muscle disorder being drug-induced?
a. Temporal relationship between the start of treatment or change in 
dose and the appearance of symptoms.
b. Lack of pre-existing muscle conditions.
c. Symptom onset within 2 years of initiation of drug therapy.
d. Partial or complete resolution after drug withdrawal.
e. Lack of any other cause of the myopathy.
5. Which of the following increases susceptibility to drug 
induced muscle disease?
a. High doses of drugs known to cause elevations in CK.
b. Advanced age.
c. Concomitant administration of corticosteroids and colchicines.
d. Concomitant hepatic failure and atorvastatin.
e. All of the above.
far more common with chloroquine (no longer available in 
Australia), than with hydroxychloroquine, the later infrequently 
occurring as a result of hydroxychloroquine intoxication, albeit 
with reduced symptoms compared to chloroquine.9
Colchicine myopathy may develop as a result of its affect 
on cellular mitosis after long term use at normal doses or 
as a result of toxicity secondary to organ failure. It presents 
most often in patients between the age of 50 and 70 years 
with mild chronic renal insufficiency,10 with symptoms of 
subacute proximal weakness, and generally in the absence 
of pain or other symptoms of colchicine toxicity. CK is 
sometimes moderately elevated.23 Patients on long-term 
colchicine therapy should be monitored for this effect.9
Penicillamine may cause inflammatory muscle disease as 
a result of an immune reaction which may occur in up to 1% 
of patients.7, 10 Myositis induced by penicillamine may occur 
at any time in the course of therapy and may also occur at 
low doses. Corticosteroid therapy is sometimes required 
to induce remission from this side effect which can take 
between six weeks and six months to be complete.7,9
Antipsychotic drug therapies that have more potent 
5-HT2A effect over dopamine D2 produce a more marked 
increase in CK than the dopamine D2 neuroleptics. CK levels 
may increase in up to 10% of patients treated with clozapine, 
risperidone, olanzapine or haloperidol.9
Drug induced causes should be considered in all patients 
presenting with muscle disorders. Observation of factors and 
drugs that may predispose a patient to drug induced muscle 
disorders should give enough clinical clues to decide if 
referral for further investigation is warranted. If drug induced 
muscle disease is detected early, potentially catastrophic 
outcomes for patients can be avoided. 
*NHFA/CSANZ – National Heart Foundation of Australia / Cardiac 
Society of Australia and New Zealand
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